Bivatuzumab mertansine

WikiDoc Resources for Bivatuzumab mertansine
Articles
Most recent articles on Bivatuzumab mertansine Most cited articles on Bivatuzumab mertansine Review articles on Bivatuzumab mertansine Articles on Bivatuzumab mertansine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bivatuzumab mertansine Images of Bivatuzumab mertansine Photos of Bivatuzumab mertansine Podcasts & MP3s on Bivatuzumab mertansine Videos on Bivatuzumab mertansine
Evidence Based Medicine
Cochrane Collaboration on Bivatuzumab mertansine Bandolier on Bivatuzumab mertansine TRIP on Bivatuzumab mertansine
Clinical Trials
Ongoing Trials on Bivatuzumab mertansine at Clinical Trials.gov Trial results on Bivatuzumab mertansine Clinical Trials on Bivatuzumab mertansine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bivatuzumab mertansine NICE Guidance on Bivatuzumab mertansine NHS PRODIGY Guidance FDA on Bivatuzumab mertansine CDC on Bivatuzumab mertansine
Books
Books on Bivatuzumab mertansine
News
Bivatuzumab mertansine in the news Be alerted to news on Bivatuzumab mertansine News trends on Bivatuzumab mertansine
Commentary
Blogs on Bivatuzumab mertansine
Definitions
Definitions of Bivatuzumab mertansine
Patient Resources / Community
Patient resources on Bivatuzumab mertansine Discussion groups on Bivatuzumab mertansine Patient Handouts on Bivatuzumab mertansine Directions to Hospitals Treating Bivatuzumab mertansine Risk calculators and risk factors for Bivatuzumab mertansine
Healthcare Provider Resources
Symptoms of Bivatuzumab mertansine Causes & Risk Factors for Bivatuzumab mertansine Diagnostic studies for Bivatuzumab mertansine Treatment of Bivatuzumab mertansine
Continuing Medical Education (CME)
CME Programs on Bivatuzumab mertansine
International
Bivatuzumab mertansine en Espanol Bivatuzumab mertansine en Francais
Business
Bivatuzumab mertansine in the Marketplace Patents on Bivatuzumab mertansine
Experimental / Informatics
List of terms related to Bivatuzumab mertansine

Overview

Bivatuzumab mertansine is a humanized monoclonal antibody and which it's used to treat squamous cancer. It has a chelator, mertansine.